Anglia Capital Group (ACG) is delighted to welcome Virilitas Labs into its investment portfolio following a £100,000 investment secured through ACG’s funding round in February. Based at Norwich Research Park, Virilitas Labs is developing rapid, at-home male fertility tests supported by AI-driven analysis — addressing a major gap in reproductive health diagnostics for men.
Co-founded by Dr Daniel Marcu and Professor Simone Immler, professor of genetics and reproduction at the University of East Anglia, the company aims to make clinic-level male fertility testing more accessible, helping reduce diagnostic delays, speed up access to treatment, and provide AI-driven personalised support at an earlier stage.
Virilitas Labs successfully navigated ACG’s rigorous screening process, impressing both the screening committee and investors with their scientific credibility, clear market understanding, and potential to make a meaningful difference in an underserved area of healthcare.
“The founders demonstrated a strong grasp of the clinical and commercial needs in this space. Their technology addresses an important issue that resonates strongly with our investors, who are committed to backing impactful innovation. We’re thrilled to welcome Virilitas Labs into the ACG portfolio and support their next stage of growth.”
Laura Hood, Operations Director at Anglia Capital Group.
What Comes Next?
The £100k investment will allow the company to strengthen its IP portfolio, optimise its rapid-testing technology, and further develop its accompanying digital platform and app, which explains individual fertility risks and provides personalised guidance.
Virilitas Labs’ momentum has also been recognised nationally: the company has been selected as one of just 15 UK businesses to join Innovate UK’s Global Business Innovation Programme in Singapore. This opportunity will help them explore international partnerships, R&D collaborations and market expansion as they continue building towards global commercialisation.
As Virilitas Labs advances its mission to transform male reproductive health, Anglia Capital Group is proud to support their journey and contribute to the growth of another high-potential, science-driven business emerging from the East of England.